{"id":"NCT01259128","sponsor":"Serenity Pharmaceuticals, Inc.","briefTitle":"Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia","officialTitle":"A Phase III Randomized, Open-Label, Multicenter Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray Formulations in Elderly Patients (â‰¥ 75 Years Old) With Nocturia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04","primaryCompletion":"2010-11","completion":"2010-11","firstPosted":"2010-12-13","resultsPosted":"2020-11-17","lastUpdate":"2020-11-17"},"enrollment":32,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Nocturia"],"interventions":[{"type":"DRUG","name":"SER120 Nasal Spray 500 ng/day","otherNames":[]},{"type":"DRUG","name":"SER120 nasal spray 750 ng/day","otherNames":[]}],"arms":[{"label":"SER120 500 ng/day","type":"EXPERIMENTAL"},{"label":"SER120 750 ng/day","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine if SER120 nasal spray is well tolerated in 75 years or older nocturic patients.","primaryOutcome":{"measure":"Serum Sodium Levels at Baseline and During Treatment","timeFrame":"baseline, Day 4, Day 8, Day 15, Day 22, Day 29, Day 43 and Day 57","effectByArm":[{"arm":"SER120 500 ng","deltaMin":141,"sd":2.4},{"arm":"SER120 750 ng","deltaMin":140,"sd":1.7}],"pValues":[]},"eligibility":{"minAge":"75 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":["nasal discomfort","sneezing","lacrimation increased","rhinorrhea","diarrhea"]}}